No data available for drug.
DRUG INTERACTION
No drug interaction found for lidocaine and .
miltefosine
may increase the risk or severity of methemoglobinemia when miltefosine is combined
ibutilide
may increase the QTc prolonging effect of QT-prolonging agents
phenazopyridine
may increase the toxic effect of Methemoglobinemia Associated Agents
bupivacaine
may have an increasingly adverse effect when combined with bupivacaine
botulinum toxin
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
abobotulinumtoxinA
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
rimabotulinumtoxinB
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
daxibotulinumtoxinA
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
prabotulinumtoxinA
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
procaine
may have an increasingly adverse effect when combined with local anesthetics
phenobarbital
may have an increasingly adverse effect when combined with local anesthetics
hydroxyurea
may have an increasingly adverse effect when combined with local anesthetics
butalbital
may have an increasingly adverse effect when combined with local anesthetics
dapsone
may have an increasingly adverse effect when combined with local anesthetics
pancuronium
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
botulinum toxin
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
abobotulinumtoxinA
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
rimabotulinumtoxinB
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
daxibotulinumtoxinA
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
abiraterone
lidocaine: they may enhance the serum concentration of CYP1A2 Inhibitors
mibefradil
lidocaine: they may enhance the serum concentration of CYP1A2 Inhibitors
diacerein
lidocaine: they may enhance the serum concentration of CYP1A2 Inhibitors
tranylcypromine
lidocaine: they may enhance the serum concentration of CYP1A2 Inhibitors
anastrozole
lidocaine: they may enhance the serum concentration of CYP1A2 Inhibitors
pinazepam
The potential for increased CNS depression risk or seriousness occurs when lidocaine is used together with pinazepam
bromazepam
when bromazepam and lidocaine are used together, there is a potential reduction in the bromazepam's metabolism
palbociclib
it increases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
mibefradil
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
amoxapine
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
nortriptyline
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
apomorphine
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
octreotide
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
procaine
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
phenobarbital
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
hydroxyurea
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
butalbital
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
dapsone
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
benzocaine
may increase the toxic effect of methemoglobinemia associated agents
hyaluronidase
may have an increasingly adverse effect when combined with local anesthetics
pancuronium
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
botulinum toxin
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
abobotulinumtoxinA
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
rimabotulinumtoxinB
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
daxibotulinumtoxinA
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
procaine
may have an increasingly adverse effect when combined with local anesthetics
phenobarbital
may have an increasingly adverse effect when combined with local anesthetics
hydroxyurea
may have an increasingly adverse effect when combined with local anesthetics
butalbital
may have an increasingly adverse effect when combined with local anesthetics
dapsone
may have an increasingly adverse effect when combined with local anesthetics
prilocaine
may increase the toxic effect of Methemoglobinemia Associated Agents
acetaminophen
may increase the adverse effect of Methemoglobinemia Associated Agents
No data available for drug.
DRUG INTERACTION
lidocaine
&
No Drug Intearction Found. for lidocaine and .
miltefosine
may increase the risk or severity of methemoglobinemia when miltefosine is combined
ibutilide
may increase the QTc prolonging effect of QT-prolonging agents
phenazopyridine
may increase the toxic effect of Methemoglobinemia Associated Agents
bupivacaine
may have an increasingly adverse effect when combined with bupivacaine
botulinum toxin
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
abobotulinumtoxinA
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
rimabotulinumtoxinB
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
daxibotulinumtoxinA
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
prabotulinumtoxinA
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
procaine
may have an increasingly adverse effect when combined with local anesthetics
phenobarbital
may have an increasingly adverse effect when combined with local anesthetics
hydroxyurea
may have an increasingly adverse effect when combined with local anesthetics
butalbital
may have an increasingly adverse effect when combined with local anesthetics
dapsone
may have an increasingly adverse effect when combined with local anesthetics
pancuronium
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
botulinum toxin
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
abobotulinumtoxinA
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
rimabotulinumtoxinB
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
daxibotulinumtoxinA
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
abiraterone
lidocaine: they may enhance the serum concentration of CYP1A2 Inhibitors
mibefradil
lidocaine: they may enhance the serum concentration of CYP1A2 Inhibitors
diacerein
lidocaine: they may enhance the serum concentration of CYP1A2 Inhibitors
tranylcypromine
lidocaine: they may enhance the serum concentration of CYP1A2 Inhibitors
anastrozole
lidocaine: they may enhance the serum concentration of CYP1A2 Inhibitors
pinazepam
The potential for increased CNS depression risk or seriousness occurs when lidocaine is used together with pinazepam
bromazepam
when bromazepam and lidocaine are used together, there is a potential reduction in the bromazepam's metabolism
palbociclib
it increases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
mibefradil
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
amoxapine
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
nortriptyline
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
apomorphine
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
octreotide
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
procaine
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
phenobarbital
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
hydroxyurea
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
butalbital
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
dapsone
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
benzocaine
may increase the toxic effect of methemoglobinemia associated agents
hyaluronidase
may have an increasingly adverse effect when combined with local anesthetics
pancuronium
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
botulinum toxin
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
abobotulinumtoxinA
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
rimabotulinumtoxinB
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
daxibotulinumtoxinA
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
procaine
may have an increasingly adverse effect when combined with local anesthetics
phenobarbital
may have an increasingly adverse effect when combined with local anesthetics
hydroxyurea
may have an increasingly adverse effect when combined with local anesthetics
butalbital
may have an increasingly adverse effect when combined with local anesthetics
dapsone
may have an increasingly adverse effect when combined with local anesthetics
prilocaine
may increase the toxic effect of Methemoglobinemia Associated Agents
acetaminophen
may increase the adverse effect of Methemoglobinemia Associated Agents
medtigo
Action and Spectrum
Drug Interaction
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Adminstartion
Patient Information Leaflet